EyePoint Pharmaceuticals, Inc. (EYPT)
$3.40-1.73%Close
SELLCRISIS · day 39
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $285M
- Beta
- 1.68
- P/E (TTM)
- -0.85
- Short % float
- 29.50%
- Days to cover
- 5.4
- SI change
- +4.9%
- 1W
- +4.62%
- 1M
- -20.00%
- vs SPY 1W
- +3.46%
- vs SPY 1M
- -22.99%
Industry peers
FMP comparable companies · ranked by market cap
- KODBUYKodiak Sciences Inc.$5.8BBULLQ 42$92.34+5.95%
- TNGXSELLTango Therapeutics, Inc.$3.6BRECOVERYQ 24$21.90+5.49%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.60+0.63%
- SEPNSELLSepterna Inc$1.6BRECOVERYQ 28$35.67+3.98%
- BCAXSELLBicara Therapeutics Inc. Common Stock$1.1BCRISISQ -9$16.56+1.39%
- SVRASELLSavara Inc.$953MRECOVERYQ 11$4.65+1.86%
- KURASELLKura Oncology, Inc.$935MBEARQ 12$10.53+0.76%
- PRMEBUYPrime Medicine, Inc.$632MRECOVERYQ -6$3.50+11.45%
- PROKSELLProKidney Corp.$538MRECOVERYQ 1$1.60+4.82%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on EYPT?
- LOPJLB’s latest quantitative signal on EyePoint Pharmaceuticals, Inc. (EYPT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is EYPT in?
- EyePoint Pharmaceuticals, Inc. (EYPT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does EyePoint Pharmaceuticals, Inc. (EYPT) do?
- EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant co…